瑞達期貨(002961.SZ)擬使用募集資金向瑞達新控增資3.5億元
格隆匯 7 月 6日丨瑞達期貨(002961.SZ)公佈,公司於2020年7月6日召開了第三屆董事會第二十次會議、第三屆監事會第十二次會議,審議通過了《關於使用募集資金對全資子公司進行增資的議案》,同意公司使用募集資金3.5億元人民幣向全資子公司瑞達新控資本管理有限公司(“瑞達新控”)進行增資。
公司此次使用募集資金對瑞達新控增資有助於提高其資本實力,滿足風險管理業務規模增長需要,進一步拓寬公司的收入渠道,增強公司的盈利能力和綜合競爭力,符合公司發展戰略及募集資金使用計劃,不會對公司財務及經營狀況產生不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.